Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 446 across all filing types
Latest filing 2023-09-18 Investor Presentation
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
益方生物关于召开2023年半年度业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the scheduling and details of a half-year performance explanation meeting (业绩说明会) for the company 益方生物科技（上海）股份有限公司. It references the company's 2023 half-year report already published on August 22, 2023, and invites investors to participate in an interactive session to discuss the half-year financial results and operational performance. The document does not contain actual financial statements or detailed financial data but rather provides logistical information about the upcoming investor meeting. This matches the characteristics of an Investor Presentation (IP) or a Call Transcript (CT) if it were a transcript. However, since this is an announcement of the meeting and its format rather than the transcript or presentation itself, it is best classified as an Investor Presentation (IP) because the meeting is described as a performance explanation session with interaction on financial results, which aligns with investor presentations. The document length is short and focused on meeting details, not the full report or transcript, so it is not an Annual Report (10-K) or Interim Report (IR).
2023-09-18 Chinese
益方生物关于持股5%以上股东权益变动达到1%的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a notification about a change in shareholding by a shareholder holding more than 5% of the company's shares. It details the change in ownership percentage, the number of shares involved, and confirms that the change does not affect control or governance. The document references relevant securities laws and disclosure obligations. This matches the definition of a Major Shareholding Notification, which involves reporting changes in significant share ownership levels crossing thresholds. The document is short and focused solely on shareholding changes, not a full financial report or other type of filing.
2023-09-11 Chinese
益方生物关于开立募集资金现金管理专用结算账户的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by the company Yifang Bio-Technology (Shanghai) Co., Ltd. regarding the opening of a dedicated settlement account for cash management of raised funds. It details the board meeting approval, account opening details, regulatory compliance, risk control measures, and the impact on the company. The document is short (1559 characters) and focuses on a specific financing-related operational update about the use and management of raised funds, not a full financial report or earnings release. It does not contain financial statements or detailed financial results. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2023-09-10 Chinese
中信证券股份有限公司关于益方生物科技（上海）股份有限公司首次公开发行部分限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (中信证券股份有限公司) regarding the listing and circulation of certain restricted shares of a company (益方生物科技(上海)股份有限公司) after its initial public offering (IPO). It references regulatory approvals, lock-up periods, shareholder commitments, and compliance with securities laws and stock exchange rules. The document is not a financial report, earnings release, or management discussion, but rather a formal regulatory compliance and verification statement related to share listing and circulation. This type of document fits best under Regulatory Filings (RNS) as it is a regulatory compliance announcement and verification opinion rather than a financial report or announcement of voting results or capital changes.
2023-09-10 Chinese
益方生物首次公开发行部分限售股上市流通公告
Regulatory Filings Classification · 95% confidence The document is an official announcement regarding the listing and circulation of previously restricted shares following the company's initial public offering (IPO). It details the number of shares becoming freely tradable, the lock-up period expiration, shareholder commitments, and regulatory compliance confirmations. The document includes specific dates, share quantities, shareholder names, and legal references. It is not a financial report, earnings release, or management discussion but rather a formal notice about the change in share status and circulation. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about share circulation and compliance, not a report or financial statement itself.
2023-09-10 Chinese
中信证券股份有限公司关于益方生物科技（上海）股份有限公司2023年上半年度持续督导跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2023年上半年度持续督导跟踪报告" which translates to "2023 First Half Year Continuous Supervision Follow-up Report". It is issued by the sponsor (中信证券股份有限公司) for the company 益方生物科技(上海)股份有限公司, related to its IPO and listing on the STAR Market (科创板). The report covers the first half of 2023, includes detailed financial data, risk factors, R&D progress, litigation updates, and usage of raised funds. It is a comprehensive mid-year report with substantive financial and operational information, not merely an announcement or certification. The document length is over 11,000 characters, indicating a full report rather than a brief notice. The content aligns with an Interim / Quarterly Report (IR) as it covers a period shorter than a full fiscal year and contains detailed financial statements and analysis. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2023
2023-09-08 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.